– GERMANY, Heilbronn – ProtaGene GmbH, a leading global contract research organization, today announced the appointment of Dr. Ray Kaiser (Ph.D.) as CEO, succeeding founder Martin Blüggel, who remains on the Board of Directors.
About Dr. Raymond Kaiser
Ray Kaiser first joined ProtaGene earlier this year as COO. He brings over 26 years of experience in the biopharmaceutical and CRO industries, including research and development, quality assurance/quality control, technical support of biopharmaceutical products, protein characterization, and application of Six Sigma methodologies. Before joining ProtaGene, Ray was the Chief Operating Officer at Nexelis, overseeing operations, business strategy, and enhanced service offerings for pre-clinical and clinical bioanalytical testing. He obtained his Ph.D. in Analytical Chemistry from Purdue University and his Master of Science in Organic Chemistry from St. Louis University. Dr. Kaiser has published over 50 papers and patents on biologics and vaccine development, manufacturing, and characterization.
“With our strong market positioning in North America and Europe, combined platforms in advanced biologic and cell and gene therapy analytical development, and focus on quality systems and strategic project management, I see no limits to what ProtaGene can accomplish,” said Dr. Ray Kaiser. “As an increasing number of novel therapeutics enter the development pipeline, ProtaGene is prepared to rise to the challenges of these new products and modalities. Ultimately, I am thrilled and privileged to lead ProtaGene as the analytic partner of choice to deliver therapeutics to patients in need quickly.”
ProtaGene is a world-leading CRO partner for the biopharmaceutical and cell and gene therapy industries. From discovery to product commercialization, ProtaGene provides the most advanced, integrated, and complete protein and gene analytic capabilities and packages. A unique combination of protein- and gene-based analytical platforms make ProtaGene the leading analytic service provider in biologics and cell and gene therapy development. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies worldwide.
For more information: https://www.protagene.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.